RxDoctor Payments Data

Victoria Sherry

Nurse Practitioner · Philadelphia, PANPI 1649376385

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 23.2%. Among nurse practitioner clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,730in general payments, 2019–2025

Across 26 payments — averaging $374.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • G1 Therapeutics, Inc.$1K
  • Amgen$1K
  • AstraZeneca$1K
  • Merck$1K
  • Regeneron Healthcare Solutions, Inc.$987
  • plus $2K from 7 others

What the payments were for

  • Consulting fees$5,35955%
  • Speaking & faculty fees$2,49626%
  • Travel & lodging$98710%
  • Food & beverage$7097%
  • Education$1792%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,730 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$22,227
Medicare patients
42
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate54$863,480
AlecensaAlectinib Hcl39$676,362
TabrectaCapmatinib Hydrochloride12$120,269
XgevaDenosumab14$44,244
EliquisApixaban14$12,418
XareltoRivaroxaban18$10,054
Dexamethasone15$286
Gabapentin14$218
Levothyroxine Sodium15$218
Lorazepam22$217
Ondansetron Hcl15$172
Omeprazole16$110
Prednisone31$92
Triamcinolone Acetonide13$12

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$1,030$863,48054 claims
AmgenXgeva$1,188$44,24414 claims
PfizerEliquis$84$12,41814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →